Compare Nu Holdings Ltd (NU) vs Summit Therapeutics Inc (SMMT) Price & Performance

NU stock trades at $14.39, up 5.89% in the last session, with a bullish technical signal from moving averages and strong fundamental growth. Revenue surged from $3.0B in 2022 to $10.63B in 2025, while net income turned positive to $2.87B. Recent news highlights expansion in Brazil and Mexico, including a new banking license, supporting continued growth momentum.

Outlook remains positive with a consensus price target of $14.98, though risks include rapid credit expansion and increased provisions. The stock offers exposure to Latin America's digital banking growth but faces execution risks in new markets and competitive pressures. Analyst sentiment is bullish with 55% buy ratings.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.